TCRX — Tscan Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $309.25m
- $176.71m
- $21.05m
Annual cashflow statement for Tscan Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -13.7 | -26.1 | -48.6 | -66.2 | -89.2 |
| Depreciation | |||||
| Non-Cash Items | 0.318 | 0.517 | 2.52 | 4.81 | 4.89 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.299 | 21.4 | -5.9 | -10.2 | 17.6 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -12.5 | -3.02 | -48.7 | -66.5 | -61.4 |
| Capital Expenditures | -1.25 | -4.24 | -9.94 | -4.22 | -3.15 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | — | — | -57.6 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -1.25 | -4.24 | -9.94 | -4.22 | -60.8 |
| Financing Cash Flow Items | — | — | — | -0.131 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 34.8 | 0.288 | 190 | 29.4 | 135 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 21 | -6.97 | 131 | -41.4 | 13.3 |